|Bid||257.01 x 1100|
|Ask||260.50 x 800|
|Day's range||253.53 - 260.50|
|52-week range||238.40 - 468.55|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||13.31|
|Earnings date||01 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||417.70|
Roche (OTC: RHHBY) is considering a launch of its Alzheimer's disease drug, gantenerumab, at a price that could undercut competition from Biogen's (NASDAQ: BIIB) Aduhelm. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss reasons why Biogen investors should be concerned if Roche's drug gains FDA approval.
(Bloomberg) -- Biogen Inc. tumbled on Friday as setbacks for its Alzheimer’s disease drug Aduhelm helped erase all the gains the stock had made in 2021.Most Read from BloombergBillionaire Family Feud Puts a Century-Old Business Empire in JeopardyAn Arab City’s Booming Art Scene Is Also a Grab at Soft PowerThe biotech stock has plunged more than 40% after reaching a six-year high in June, when Aduhelm was approved. The decline has wiped out more than $26 billion in Biogen’s market value. On Frida
Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.